148 related articles for article (PubMed ID: 27481948)
1. How Public-Private Collaborations Are Driving Solutions to the Antibacterial Drug Development Crisis.
Madre L; Tenaerts P
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S25-6. PubMed ID: 27481948
[No Abstract] [Full Text] [Related]
2. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
[TBL] [Abstract][Full Text] [Related]
3. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
[TBL] [Abstract][Full Text] [Related]
4. Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.
Toerner JG; Rubin D
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S37-8. PubMed ID: 27481951
[TBL] [Abstract][Full Text] [Related]
5. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
[TBL] [Abstract][Full Text] [Related]
6. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Jones RN
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
[TBL] [Abstract][Full Text] [Related]
7. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
Talbot GH
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
[TBL] [Abstract][Full Text] [Related]
8. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
[TBL] [Abstract][Full Text] [Related]
9. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
[TBL] [Abstract][Full Text] [Related]
10. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Talbot GH; Das A; Cush S; Dane A; Wible M; Echols R; Torres A; Cammarata S; Rex JH; Powers JH; Fleming T; Loutit J; Hoffmann S;
J Infect Dis; 2019 Apr; 219(10):1536-1544. PubMed ID: 30649434
[TBL] [Abstract][Full Text] [Related]
11. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
[TBL] [Abstract][Full Text] [Related]
12. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
[TBL] [Abstract][Full Text] [Related]
13. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
Bartlett JG; Barie PS; Niederman MS; Wunderink RG
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
[No Abstract] [Full Text] [Related]
14. The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.
François B; Chastre J; Eggiman P; Laterre PF; Torres A; Sanchez M; Esser MT; Bishop B; Bonten M; Goosens H; Jafri HS
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S46-51. PubMed ID: 27481953
[TBL] [Abstract][Full Text] [Related]
15. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
16. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
; ; ; ; Spellberg B; Talbot G
Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S150-70. PubMed ID: 20597666
[No Abstract] [Full Text] [Related]
17. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia and ventilator‐associated pneumonia. Proceedings of a workshop co-sponsored by the US Food and Drug Administration, Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine. March 31-April 1 2009.
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-170. PubMed ID: 21058464
[No Abstract] [Full Text] [Related]
18. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
Barriere SL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
[TBL] [Abstract][Full Text] [Related]
20. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
